Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients.

BackgroundThe decrease in prostaglandin E2 (PGE2) release due to aspirin (ASA)-induced cyclooxygenase inhibition and the increment in cysteinyl leukotriene (Cys-LT) release secondary to the removal of the inhibitory effect of PGE2 on Cys-LT release have been suggested in the pathogenesis of aspirin-induced asthma (AIA). ObjectiveIn this study, we aimed to investigate the in vitro release of Cys-LT and to determine the effect of PGE2 on Cys-LT release from peripheral blood leucocytes of patients with AIA after stimulation by ASA. Patients and methodsPatients with AIA (n = 13), patients with ASA-tolerant asthma (ATA) (n = 12) and healthy volunteers as controls (n = 13) were included to the study. ASA and PGE2 at three different concentrations were applied to the peripheral blood leucocytes of the study group, and Cys-LT levels following stimulants were assessed by enzyme immunoassay method. ResultsThere was no difference in baseline Cys-LT levels between groups (AIA 353.4 ± 55.5 pg/mL, ATA 354.7 ± 40.3 pg/mL, and control group 368.5 ± 30.2 pg/mL; P > 0.05). Though not present in other groups, the Cys-LT level of 453.6 ± 70.0 pg/mL following ASA stimulation was higher than baseline in patients with AIA (P = 0.04). When PGE2 was added to the ASA-stimulated samples of patients with AIA, Cys-LT levels were measured as 298.7 ± 78.6 pg/mL, 279.8 ± 79.9 pg/mL, and 243.4 ± 51.3 pg/mL at PGE2 10-7 m, 10-6 m and 10-5 m concentrations, respectively. These levels were lower than the ASA-stimulated Cys-LT values (P = 0.03, P = 0.01 and P = 0.01, respectively). The inhibitory effect of different PGE2 concentrations on Cys-LT release was also present in patients with ATA and in controls. ConclusionThe increase in Cys-LT levels following ASA stimulation seems to be unique to AIA, which was not present in patients with ATA and... [ABSTRACT FROM AUTHOR]